Johnson & Johnson Completes Acquisition of Shockwave Medical
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Shockwave Medical, integrating it as a business unit within Johnson & Johnson MedTech. This strategic move aims to enhance Johnson & Johnson's position in the cardiovascular intervention sector. Shockwave Medical is renowned for its intravascular lithotripsy (IVL) platform, used to treat coronary and peripheral artery diseases. The acquisition is projected to support revenue growth and strengthen Johnson & Johnson MedTech’s market leadership. However, the transaction will likely dilute adjusted earnings per share by $0.10 in 2024 and $0.17 in 2025 due to financing costs. Shockwave's common stock has ceased trading on NASDAQ.
- Strengthens Johnson & Johnson's leadership in cardiovascular intervention.
- Integrates Shockwave’s innovative IVL technology into Johnson & Johnson MedTech.
- Expected to accelerate revenue growth for Johnson & Johnson and Johnson & Johnson MedTech.
- Shockwave Medical to become Johnson & Johnson MedTech’s thirteenth priority platform, aiming for annual sales of at least $1 billion.
- Transaction expected to dilute adjusted earnings per share by $0.10 in 2024.
- Further dilution anticipated with $0.17 EPS decrease in 2025 due to financing costs.
- Shockwave's common stock has ceased trading on NASDAQ, ending its public market presence.
Insights
Johnson & Johnson's acquisition of Shockwave Medical represents a substantial strategic move for the company, especially in the high-growth sector of cardiovascular intervention. The transaction is expected to be accretive to Johnson & Johnson's operating margin, demonstrating a likely positive impact on profitability, despite an anticipated dilution in adjusted earnings per share by approximately
With Shockwave's intravascular lithotripsy (IVL) platform targeting coronary artery disease (CAD) and peripheral artery disease (PAD), Johnson & Johnson is positioned to tap into a market with considerable unmet medical needs. This alignment with high-growth markets can drive substantial revenue over time, justifying the short-term financial trade-offs observed.
The acquisition of Shockwave Medical by Johnson & Johnson is particularly noteworthy due to Shockwave's intravascular lithotripsy (IVL) technology. IVL is used to treat calcified artery disease, a condition where calcium deposits in coronary and peripheral arteries make them hard and difficult to treat with conventional methods. Shockwave’s technology uses sonic pressure waves to break up these calcified plaques, allowing for easier and more effective stent placement. This innovative approach has been a game-changer in treating cardiovascular conditions and aligns well with Johnson & Johnson's existing cardiovascular portfolio.
From a clinical standpoint, this acquisition enhances Johnson & Johnson's ability to provide comprehensive treatment solutions across a spectrum of cardiovascular diseases, potentially improving patient outcomes and broadening the company's market reach. The synergy between Shockwave's technology and Johnson & Johnson's existing expertise could lead to further innovations and advancements in the field.
Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention
Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.”
Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry. Shockwave’s differentiated solutions and robust pipeline represent an exciting opportunity for Johnson & Johnson MedTech to bring more innovations to patients in one of the largest areas of unmet medical need. We are excited to begin collaborating directly with the Shockwave team and look forward to a bright future together.”
This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson & Johnson’s leading positions in heart recovery (Abiomed) and electrophysiology (Biosense Webster) to make it a category leader in four of the largest and highest-growth medtech markets within cardiovascular intervention.
Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least
In connection with the completion of the transaction, Shockwave’s common stock ceased trading on NASDAQ.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.
Cautions Concerning Forward-Looking Statements
- This communication contains “forward-looking statements” regarding the acquisition of Shockwave by Johnson & Johnson.
- The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.
- If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson or Shockwave. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment.
- In addition, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the programs, products, technologies and employees/operations and clinical work of Shockwave. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Shockwave can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 16, 2024, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in Johnson & Johnson’s most recently filed Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 1, 2024, in Johnson & Johnson’s subsequent filings with the SEC and in Shockwave’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 26, 2024, including in the sections captioned “Special Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in Shockwave’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the SEC on May 6, 2024, and in Shockwave’s subsequent filings with the SEC. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, https://shockwavemedical.com/ or on request from Johnson & Johnson or Shockwave. Neither Johnson & Johnson nor Shockwave undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530938029/en/
Johnson & Johnson
Media Contact:
Ryan Carbain
media-relations@its.jnj.com
Investor Contact:
Tracy Menkowski
investor-relations@its.jnj.com
Source: Johnson & Johnson
FAQ
What company did Johnson & Johnson acquire?
What is the significance of Johnson & Johnson's acquisition of Shockwave Medical?
How does the Shockwave acquisition impact Johnson & Johnson's revenue?
What is the financial impact of the Shockwave acquisition on Johnson & Johnson's earnings?
What happened to Shockwave Medical's stock after the acquisition?
